KAT5 and hepatocellular carcinoma: Notably, Cas9 RNP targeting lysine acetyltransferase 5 (KAT5) can suppress the growth of HCC, which suggests that therapeutics involving the editing of other HCC-related genes hold vast potential for treatment [131].